LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis

20251 citationsJournal Articlegold Open Access

Authors

E. Krecipro-Nizinska · Wrocław University of Science and Technology

Wojciech Pluskiewicz · Medical University of Silesia

Jerzy Supronik · Anna Needs Neuroblastoma Answers

Peter Szeles · Fresenius Kabi (Czechia)

Corinne Petit-Frère · Fresenius Kabi (Czechia)

Ersilia Varone · Fresenius Kabi (Czechia)

Serge Ferrari

Abstract

This study demonstrated therapeutic equivalence of, and comparable pharmacokinetics, safety, and immunogenicity profiles between FKS518 and reference denosumab, completing the clinical evidence to propose FKS518 as a biosimilar to denosumab.

Topics & Keywords

Publication Details

Published in: Journal of the Endocrine Society

Volume 9, Issue 12, pp. bvaf164-bvaf164

DOI: 10.1210/jendso/bvaf164

Field-Weighted Citation Impact: 0.81

Command Palette

LUMIADE 3: Therapeutic Equivalence of Denosumab Biosimilar FKS518 to Reference Product in Postmenopausal Osteoporosis

Authors

Abstract

Topics & Keywords

Publication Details